Background: Although prostate cancer has recently registered increasing incidence and decreasing mortality in Spain, no analysis has yet been made of these two indicators to ascertain the magnitude of and reasons for these trends.
introduction
Prostate cancer is the second leading cancer diagnosed among men (after lung cancer), and the sixth leading cause of cancer death worldwide [1] . Prostate cancer is particularly prevalent in developed countries, such as the USA and Scandinavia, with an approximately 6-fold difference between high-incidence and low-incidence countries [2, 3] . According to estimates for 2006, Spain's incidence rates are low vis-à-vis European Union countries and intermediate when compared with all European countries as a whole [4] . In recent decades, while incidence has increased in most developed countries [3, 5] including Spain, there has been a simultaneous widespread reduction in prostate cancer mortality rates in developed countries [1, 6] . Declines in mortality are similarly evident in 14 out of Spain's 17 autonomous regions [Comunidades Autónomas] [7] .
When it comes to interpreting time trends in prostate cancer incidence and mortality, two types of factors may be involved. First, there may be a real increase in incidence due to increased exposure to one or more risk factors. The only well-established risk factors for prostate cancer are age, race/ethnicity [8] and family history [9] . Other risk factors, such as diet [10, 11] and obesity [12] , are unclear. Human prostate carcinomas are usually androgen sensitive, suggesting that steroid hormones play a role in human prostate carcinogenesis [13] . Secondly, there may be increased detection of existing tumours by transurethral resection (TURP) [14, 15] and the prostatespecific antigen (PSA) test [16] . This study describes prostate cancer incidence trends in the area jointly covered by 13 Spanish cancer registries over the period , both overall and by age group, along with the mortality caused by this cancer in Spain.
patients and methods

data source
All invasive prostate cancers registered at 13 Spanish population-based cancer registries from 1975 to 2004 were included in the study. The number of invasive prostate cancer cases, broken down by 5-year age group (0-4, 5-9, . , 80-84 and ‡85 years) and single year of diagnosis, was provided by all Spanish population-based cancer registries that had data for at least nine consecutive years over the period . Invasive cases of prostate cancer corresponded to code 185 of the ninth revision and code C61 of the 10th revision of the International Classification of Diseases. Overall, the 13 registries included in the study covered 27.7% (5 576 387 men) of the total Spanish male population (Census 2001). Insofar as Spanish mortality data were concerned, the number of deaths due to prostate cancer which occurred during the period 1980-2007, broken down by age, were drawn from the official files of the Spanish National Statistics Institute (Instituto Nacional de Estadística). Estimates of the mid-year male populations covered by these registries during the study period were obtained from the Spanish National and Regional Institutes of Statistics.
statistical analysis
Age-standardised prostate cancer incidence rates were calculated for each registry and 5-year period (1975-79, 1980-84, 1985-89, 1990-94, 1995-99 and 2000-04) using the direct method with the European standard population. Assuming a Poisson distribution for the number of cases broken down by registry, 5-year period and age group, the ratio of the agestandardised rates (ASRs) and its 95% confidence interval (CI) were computed for each individual registry, taking the average for all Spanish registries for each 5-year period as reference.
Changes in age-and registry-adjusted incidence and mortality rates over the study period were evaluated using change-point Poisson models [17] . This change-point model is similar to the widely used joinpoint regression [18] but, instead of assuming an overall trend consisting of intersecting linear segments with an implausible sharp bend at the change-point, the proposed model allows for more gradual transitions between the linear trends. This change-point model was fitted using grid search methods, and it provided an asymptotic test for the existence of a change-point, the estimate and 95% CI for the location of the change-point, and the estimates and 95% CIs for the annual percentage changes (APCs) in incidence rates below and above the change-point. Further methodological details are provided elsewhere [19] .
Owing to the limited number of prostate cancer cases among subjects aged <45 years (n = 89), these age groups were excluded from all trend analyses. The models described above were also used to evaluate the specific evolution of prostate cancer incidence and mortality among subjects aged 45-64 and ‡65 years. Incidence time trends were also analysed separately in those registries with at least 15 years of uninterrupted registration.
Log-linear Poisson models were fitted to study the effect of age, period and birth cohort. To avoid the 'non-identifiability' problem, we used Osmond and Gardner's [20] and Decarli and La Vecchia's [21] solutions. Age groups <45 years were also excluded from this analysis.
results
A total of 58 559 incident cases of prostate cancer were identified from among the 93 043 501 man-years covered by the registries from 1975 to 2004. Overall, ASRs increased from 31.5 to 86.6 cases per 100 000 man-years across the study period, with a much more marked increase in the last decade. The percentage of cases aged ‡65 years remained unchanged from 1975-79 to 1990-94 and then decreased from 87% in 1990-94 to 79% in 2000-04, with noticeable geographical differences occurring, particularly during the last quinquennium. Most areas displayed a slightly upward trend until 1990-94. This rising trend accelerated to differing degrees during the last decade, and widened the differences in ASR between areas: in 2000-04, areas that registered the highest incidences had rate ratios with respect to all the registries combined of 1.20, whereas areas with the lowest incidences had rate ratios of 0.57 and 0.69 (Table 1 ). Figure 1A shows the age-and registry-adjusted incidence rates by single year of diagnosis among men aged ‡45 years, for Spanish registries as a whole, along with the estimated time trend obtained by fitting a change-point model. The changepoint model indicated a statistically significant change in trend in 1990. Incidence rates plotted a significant annual increase of 1.3% before 1990 and an increase of 7.3% thereafter. In the analysis by age group (45-64 years and 65+ years), both groups displayed a significant change-point in 1990: in the youngest age group, the APC was 1.4 (not statistically significant) before 1990, followed by a sharp increase in the rate, with an APC of 14.6; among men in the oldest age group, there was a significant APC of 1.4 before 1990, followed by an APC of 5.8 in the period 1990-2004 (Table 2 ). Figure 2 shows that there were clear age, period and cohort effects in incidence. A greater increase in incidence appeared from about 1990, and among cohorts born from 1925 to 1934, such that the more recent the birth cohort, the steeper the increase. A decrease in incidence was observed in the 80-84 and 85+ age groups in the last quinquennium.
Mortality, on the other hand, rose by 0.7% per annum from 1980 to 1998, after which it declined by 3.6% per annum until 2007 (Table 2) . A very similar trend pattern was observed for both age groups ( Figure 1B ).
discussion
This study shows that in Spain incidence of prostate cancer increased by 1.3% per annum from 1975 until a change-point in 1990, and even more sharply thereafter (7.3% per annum). Incidence rates for the period 2000-04 were more than double those for 1990-94. Subsequently, the pattern of evolution differed according to age group. Whereas the percentage increase was low and similar for both age groups until 1990, this was followed by a steeper rise in both age groups and among younger men in particular (ages 45-65 years), with a decline being observed solely in the 80-84 and 85+ age groups in the last quinquennium. Analysis of registries with at least 15 years of uninterrupted registration shows that trends in incidence were not consistent across geographical areas, with two different patterns being in evidence, namely, one group with a change-point in around 1990 (Zaragoza and Tarragona), and another group without any change-point, in which incidence increased steadily across the entire study period original article (Navarre, Murcia, Granada and Basque Country) (data not shown).
The results of this study are strengthened by the inclusion of the latest available data from all population-based Spanish cancer registries with a minimum of 9 years of uninterrupted registration and by the use of appropriate statistical methods to detect trend changes.
Some limitations of the present study may compromise generalisation and comparability. Firstly, the population covered by the registries is located mainly in the north and east of Spain, and so observed trends in prostate cancer incidence might not be totally generalisable to the rest of the country. Secondly, the starting year of data collection varied widely across registries, ranging from 1975 to 1996, and, moreover, five of them had not retrieved information before the identified change-point. Thirdly, biased results may stem from variation in data quality between cancer registries; and, while marked differences would compromise comparability, it has to be said that the quality indicators were acceptable for all of them [5] . Fourthly, serious reporting delays could create an artefact of apparently decreasing rates at the end of the series. Nevertheless, no decrease was observed in the overall incidence trend at the end of the study period, and only a decline in incidence among the oldest age groups (ages 80-84 and 85+ years) was observed as result of early diagnosis in younger men, a finding in line with those from other countries [22] [23] [24] [25] . Finally, as population-based data on PSA-testing trends in Spain are non-existent, we were unable to correlate the population the prevalence of PSA testing and the incidence of prostate cancer.
Interpretation of prostate cancer incidence requires an understanding of multiple interacting factors. Though not well understood, several factors, such as diet, body mass index, androgen metabolism and genetics, have been proposed to explain the aetiology of this cancer [26] . The prevalence of obesity among Spanish men aged 18+ years went from 6.9% in 1987 to 12.3% in 2001 [27] . Other risk factors may have had a role in this increase in incidence. Nevertheless, changes in the prevalence of risk factors might be only partially responsible for the increase in prostate cancer incidence. Better access to health services and the introduction into routine clinical practice of therapeutic modalities such as TURP and diagnostic procedures such as echo-guided biopsy, transrectal ultrasonography and PSA testing, can be assumed to have made a greater contribution to this increase as a result of an enhanced capability to detect incidental cancers that would otherwise be latent [14] [15] [16] 28] . Thus, incidence may be distorted by the inclusion of varying numbers of so-called latent cancers. The increase in incidence during the late 1970s and the 1980s has been correlated with an increased use of TURP in some countries [14, 25, 29] . In contrast, the rapid increase in incidence seen in the USA just before and during the 1990s coincided with the introduction of the PSA test [30] [31] [32] [33] .
Incidence trends in countries with a higher uptake of PSA testing showed a consistent pattern, marked by a rapid rise in incidence soon after the introduction of PSA, followed by a sharp downward turn and, finally, a steady increase in rates [22, 24, 31, 34, 35] . In other countries, the incidence of prostate cancer was reported to be steadily increasing during the pre-PSA era and the rate of change became more pronounced Per 100 000 European standard population. % ‡65y: percentage of cases aged ‡65 years; ASR: age-standardised rate; RR (95% CI): age-standardised rate ratio (95% CI) for each registry with respect to all registries combined in the corresponding 5-year period.
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during the 1990s [2, 29, 30, 36, 37] . Lastly, there is a group of countries with low levels of PSA testing, such as Japan and other countries in Asia [3] , which have registered consistent, albeit small, increases in incidence during the 1980s, 1990s and 2000s.
In Spain, where the background incidence rate in 1975 was relatively low, there was a slight rise in incidence in the pre-PSA era, probably due to the introduction of TURP followed by 15 years of sharp increases, and it would appear that the rates have not yet peaked. The increased incidence observed in the second period of our study occurred during a period of major changes in diagnostic techniques, and much of the observed period effect, as well as the geographic variation, are principally due to an increasing detection rate following the introduction Figure 1 . Prostate cancer trends by age group: age-and registry-adjusted incidence rates in areas of Spain covered by cancer registries , and ageadjusted mortality rates in Spain (1980 Spain ( -2007 . The observed rates (dotted line) were obtained by using nominal categories for single year of diagnosis, and the estimated time trend (solid line) and its 95% confidence interval (CI) (shaded region) were obtained by fitting a change-point model (see Methods section). APC, annual percentage change.
of the PSA test. This pattern and the non-existence of a peak in the rates is the result of the gradual introduction of PSA testing, not only throughout the country as a whole, but also in each of the regions.
This study confirms regional differences in cancer incidence in Spain, yet these differences seem to have widened during the last part of the study period, due in all likelihood to variations in the prevalence of PSA testing. The northern areas of Navarre, the Basque Country and Girona, together with the Canary Islands, registered the highest incidence in this period, with rates exceeding the overall estimates for Spain. This northsouth gradient in incidence may be associated with the different spread of PSA testing in different parts of the country. An analysis of the variations in the use of prostatectomy in Spain revealed enormous differences between health areas (with a clear north-south geographical pattern), and the authors concluded that these variations were explained by opportunistic screening rather than by differences in incidence [38] .
While the direct consequence of PSA testing might be a reduction in prostate-cancer-specific mortality [7, 23, [39] [40] [41] , the first noticeable consequences are an increase in incidental/ low-risk tumours [42] [43] [44] [45] and a reduction in average age at diagnosis and the proportion of cancers diagnosed among the oldest men. Despite the fact that the Spanish population aged from 1980 to 2004, this occurred in most areas of Spain. Yet, Girona, which registered one of the highest incidence rates during the last 5-year period, also had a very high proportion of cases among men aged ‡65 years. In countries where PSA testing has been more common (such as the USA and Australia), this proportion decreased by between 10 and 20 points, and in countries with a lower prevalence of PSA testing, this percentage remained practically unchanged. Nevertheless, as reported by Pashayan et al. [46] , the benefit of screening in reducing advanced-stage disease is limited by overdiagnosis, which is greater among older men. Overdiagnosis is the most important side-effect of prostate cancer screening. The number of additional treated prostate cancers to prevent one death has been estimated at 48 by the European Randomised Study of Screening for Prostate Cancer [47] ; and in the USA, Welch and Albertsen [48] estimated these additional treated cases at >20 per avoided death.
Since screening implies earlier diagnosis for many patients and an increase in the diagnosis of low-risk cancers, an increase in survival, more marked than that for any other cancer, has been described in Europe, dating from the late 1970s to the present day. Differences in 5-year relative survival, both between countries-ranging from 80% (Canada and Austria) or higher in the USA (92%) to <40% (Denmark, Poland and Algeria)-and within countries, have been described in the CONCORD study [49] , reflecting differences in the early detection of these tumours. According to the EUROCARE project, relative survival rates for prostate cancer in Spain went from 54% in 1985-89 to 75% in 1995-99 [50] . Although some role could be attributed to improvements in therapy, the greatest part of this increase can be assumed to be caused by the screening effect.
Decreasing trends in mortality have been described worldwide [23, 39, 51] but in some countries these trends were detected even before the screening effect should have become noticeable. In Spain, the decreasing trend in mortality appeared in 1998, a full 8 years after the change-point in incidence and, as in every other country with screening, its magnitude was lower than that of changes observed in survival affected by overdiagnosis.
Since PSA testing is becoming increasingly widespread in Spain, it is likely that, in the near future, the incidence of prostate cancer will either remain stable or increase, and therefore the number of low-risk cancers diagnosed will likewise stay at current levels or rise. Should this happen, regardless of its effect on mortality, overdiagnosis and overtreatment engendered by PSA-based screening could become chronic side-effects, and prostate cancer, by reason of both its incidence and its prevalence, will come to represent a greater health problem requiring and using ever more health resources. 
